FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2154616892> ?p ?o ?g. }

• W2154616892 endingPage "154" @default.
• W2154616892 startingPage "145" @default.
• W2154616892 abstract "Oral phosphodiesterase (PDE) 4 inhibitors such as roflumilast have established the potential of PDE4 inhibition for the treatment of respiratory diseases. However, PDE4 inhibitor efficacy is limited by mechanism-related side effects such as emesis and nausea. Delivering the inhibitor by the inhaled route may improve therapeutic index, and we describe 6-({3-[(dimethylamino)carbonyl]phenyl}sulfonyl)-8-methyl-4-{[3-methyloxy) phenyl]amino}-3-quinolinecarboxamide (GSK256066), an exceptionally high-affinity inhibitor of PDE4 designed for inhaled administration. GSK256066 is a slow and tight binding inhibitor of PDE4B (apparent IC₅₀ 3.2 pM; steady-state IC₅₀ <0.5 pM), which is more potent than any previously documented compound, for example, roflumilast (IC₅₀ 390 pM), tofimilast (IC₅₀ 1.6 nM), and cilomilast (IC₅₀ 74 nM). Consistent with this, GSK256066 inhibited tumor necrosis factor α production by lipopolysaccharide (LPS)-stimulated human peripheral blood monocytes with 0.01 nM IC₅₀ (compared with IC₅₀ values of 5, 22, and 389 nM for roflumilast, tofimilast, and cilomilast, respectively) and by LPS-stimulated whole blood with 126 pM IC₅₀. GSK256066 was highly selective for PDE4 (>380,000-fold versus PDE1, PDE2, PDE3, PDE5, and PDE6 and >2500-fold against PDE7), inhibited PDE4 isoforms A-D with equal affinity, and had a substantial high-affinity rolipram binding site ratio (>17). When administered intratracheally to rats, GSK256066 inhibited LPS-induced pulmonary neutrophilia with ED₅₀ values of 1.1 μg/kg (aqueous suspension) and 2.9 μg/kg (dry powder formulation) and was more potent than an aqueous suspension of the corticosteroid fluticasone propionate (ED₅₀ 9.3 μg/kg). Thus, GSK256066 has been demonstrated to have exceptional potency in vitro and in vivo and is being clinically investigated as a treatment for chronic obstructive pulmonary disease." @default.
• W2154616892 created "2016-06-24" @default.
• W2154616892 creator A5005572883 @default.
• W2154616892 creator A5017647781 @default.
• W2154616892 creator A5019043835 @default.
• W2154616892 creator A5030691488 @default.
• W2154616892 creator A5032968420 @default.
• W2154616892 creator A5033925406 @default.
• W2154616892 creator A5049569160 @default.
• W2154616892 creator A5056115689 @default.
• W2154616892 creator A5061287908 @default.
• W2154616892 creator A5062149063 @default.
• W2154616892 creator A5075303013 @default.
• W2154616892 creator A5089550449 @default.
• W2154616892 creator A5091837489 @default.
• W2154616892 date "2011-01-04" @default.
• W2154616892 modified "2023-10-01" @default.
• W2154616892 title "GSK256066, an Exceptionally High-Affinity and Selective Inhibitor of Phosphodiesterase 4 Suitable for Administration by Inhalation: In Vitro, Kinetic, and In Vivo Characterization" @default.
• W2154616892 cites W1498674265 @default.
• W2154616892 cites W1510098440 @default.
• W2154616892 cites W1516350423 @default.
• W2154616892 cites W1590375747 @default.
• W2154616892 cites W1977177612 @default.
• W2154616892 cites W1980481083 @default.
• W2154616892 cites W1984219340 @default.
• W2154616892 cites W1984282650 @default.
• W2154616892 cites W1995669956 @default.
• W2154616892 cites W2010910086 @default.
• W2154616892 cites W2017659011 @default.
• W2154616892 cites W2028109077 @default.
• W2154616892 cites W2029944874 @default.
• W2154616892 cites W2045875906 @default.
• W2154616892 cites W2067809779 @default.
• W2154616892 cites W2077451485 @default.
• W2154616892 cites W2088855906 @default.
• W2154616892 cites W2129558854 @default.
• W2154616892 cites W2133369375 @default.
• W2154616892 cites W2164508592 @default.
• W2154616892 cites W2316875009 @default.
• W2154616892 cites W2335515876 @default.
• W2154616892 cites W4237807778 @default.
• W2154616892 doi "https://doi.org/10.1124/jpet.110.173690" @default.
• W2154616892 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21205923" @default.
• W2154616892 hasPublicationYear "2011" @default.
• W2154616892 type Work @default.
• W2154616892 sameAs 2154616892 @default.
• W2154616892 citedByCount "58" @default.
• W2154616892 countsByYear W21546168922012 @default.
• W2154616892 countsByYear W21546168922013 @default.
• W2154616892 countsByYear W21546168922014 @default.
• W2154616892 countsByYear W21546168922015 @default.
• W2154616892 countsByYear W21546168922016 @default.
• W2154616892 countsByYear W21546168922017 @default.
• W2154616892 countsByYear W21546168922018 @default.
• W2154616892 countsByYear W21546168922019 @default.
• W2154616892 countsByYear W21546168922020 @default.
• W2154616892 countsByYear W21546168922021 @default.
• W2154616892 countsByYear W21546168922022 @default.
• W2154616892 countsByYear W21546168922023 @default.
• W2154616892 crossrefType "journal-article" @default.
• W2154616892 hasAuthorship W2154616892A5005572883 @default.
• W2154616892 hasAuthorship W2154616892A5017647781 @default.
• W2154616892 hasAuthorship W2154616892A5019043835 @default.
• W2154616892 hasAuthorship W2154616892A5030691488 @default.
• W2154616892 hasAuthorship W2154616892A5032968420 @default.
• W2154616892 hasAuthorship W2154616892A5033925406 @default.
• W2154616892 hasAuthorship W2154616892A5049569160 @default.
• W2154616892 hasAuthorship W2154616892A5056115689 @default.
• W2154616892 hasAuthorship W2154616892A5061287908 @default.
• W2154616892 hasAuthorship W2154616892A5062149063 @default.
• W2154616892 hasAuthorship W2154616892A5075303013 @default.
• W2154616892 hasAuthorship W2154616892A5089550449 @default.
• W2154616892 hasAuthorship W2154616892A5091837489 @default.
• W2154616892 hasBestOaLocation W21546168922 @default.
• W2154616892 hasConcept C126322002 @default.
• W2154616892 hasConcept C150903083 @default.
• W2154616892 hasConcept C181199279 @default.
• W2154616892 hasConcept C185592680 @default.
• W2154616892 hasConcept C202751555 @default.
• W2154616892 hasConcept C207001950 @default.
• W2154616892 hasConcept C26291073 @default.
• W2154616892 hasConcept C2776766087 @default.
• W2154616892 hasConcept C2776780178 @default.
• W2154616892 hasConcept C2776958096 @default.
• W2154616892 hasConcept C2778926808 @default.
• W2154616892 hasConcept C55493867 @default.
• W2154616892 hasConcept C62826618 @default.
• W2154616892 hasConcept C71924100 @default.
• W2154616892 hasConcept C86803240 @default.
• W2154616892 hasConcept C98274493 @default.
• W2154616892 hasConceptScore W2154616892C126322002 @default.
• W2154616892 hasConceptScore W2154616892C150903083 @default.
• W2154616892 hasConceptScore W2154616892C181199279 @default.
• W2154616892 hasConceptScore W2154616892C185592680 @default.
• W2154616892 hasConceptScore W2154616892C202751555 @default.
• W2154616892 hasConceptScore W2154616892C207001950 @default.
• W2154616892 hasConceptScore W2154616892C26291073 @default.
• W2154616892 hasConceptScore W2154616892C2776766087 @default.

• next